IO Biotech Inc
IOBT0.350USD
+0.030+9.27%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
24.39MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über IO Biotech Inc Unternehmen
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO Biotech Inc Informationen
BörsenkürzelIOBT
Name des UnternehmensIO Biotech Inc
IPO-datumNov 05, 2021
CEOZocca (Mai-Britt)
Anzahl der mitarbeiter80
WertpapierartOrdinary Share
GeschäftsjahresendeNov 05
AddresseOle Maaloes Veh 3
StadtCOPENHAGEN
BörseNASDAQ OMX - NASDAQ BASIC
LandDenmark
Postleitzahl2200
Telefon4570702980
Websitehttps://www.iobiotech.com/
BörsenkürzelIOBT
IPO-datumNov 05, 2021
CEOZocca (Mai-Britt)
Führungskräfte von IO Biotech Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+12000.00%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
+15000.00%
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
--
--
Ms. Amy B. Sullivan
Ms. Amy B. Sullivan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Qasim Ahmad, M.D.
Dr. Qasim Ahmad, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+12000.00%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
+15000.00%
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Ikarian Capital LLC
2.12%
Andere
58.69%
Aktionäre
Aktionäre
Anteil
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Ikarian Capital LLC
2.12%
Andere
58.69%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
29.12%
Investment Advisor
6.63%
Hedge Fund
5.28%
Individual Investor
5.14%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.26%
Andere
50.20%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
52
34.65M
48.27%
-16.00M
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lundbeckfond Ventures
13.95M
19.39%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
9.48%
--
--
Apr 11, 2025
HBM Partners AG
3.94M
5.48%
--
--
Apr 11, 2025
Chernett (Jorey)
3.48M
4.83%
+3.48M
--
Oct 30, 2025
Ikarian Capital LLC
1.53M
2.12%
+1.53M
--
Sep 30, 2025
Millennium Management LLC
1.39M
1.94%
+1.39M
--
Sep 30, 2025
Marshall Wace LLP
1.05M
1.46%
-1.05M
-50.00%
Sep 30, 2025
BofA Global Research (US)
799.95K
1.11%
-815.12K
-50.47%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
668.40K
0.93%
+14.72K
+2.25%
Sep 30, 2025
Boothbay Fund Management, LLC
591.18K
0.82%
+591.18K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
